Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 2
1955 1
1956 1
1957 1
1958 2
1959 2
1960 1
1963 3
1964 1
1966 4
1967 2
1968 4
1969 6
1970 4
1971 3
1972 7
1973 5
1974 11
1975 13
1976 12
1977 12
1978 15
1979 13
1980 20
1981 16
1982 21
1983 22
1984 29
1985 28
1986 30
1987 35
1988 33
1989 42
1990 35
1991 45
1992 59
1993 54
1994 80
1995 72
1996 87
1997 95
1998 82
1999 91
2000 82
2001 73
2002 70
2003 78
2004 42
2005 65
2006 75
2007 82
2008 76
2009 91
2010 93
2011 106
2012 83
2013 87
2014 125
2015 116
2016 101
2017 136
2018 134
2019 110
2020 154
2021 167
2022 176
2023 179
2024 167

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,437 results

Results by year

Filters applied: . Clear all
Page 1
Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC.
Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, Goto Y, Takeshita M, Harada T, Hirano K, Oguri T, Kondo M, Miura S, Hosomi Y, Kato T, Kubo T, Kishimoto J, Yamamoto N, Nakanishi Y, Okamoto I. Yoneshima Y, et al. Among authors: ando m. J Thorac Oncol. 2021 Sep;16(9):1523-1532. doi: 10.1016/j.jtho.2021.03.027. Epub 2021 Apr 27. J Thorac Oncol. 2021. PMID: 33915251 Free article. Clinical Trial.
Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trial.
Kataoka K, Nishiyama O, Ogura T, Mori Y, Kozu R, Arizono S, Tsuda T, Tomioka H, Tomii K, Sakamoto K, Ishimoto H, Kagajo M, Ito H, Ichikado K, Sasano H, Eda S, Arita M, Goto Y, Hataji O, Fuke S, Shintani R, Hasegawa H, Ando M, Ogawa T, Shiraishi M, Watanabe F, Nishimura K, Sasaki T, Miyazaki S, Saka H, Kondoh Y; FITNESS study Collaborators. Kataoka K, et al. Among authors: ando m. Thorax. 2023 Aug;78(8):784-791. doi: 10.1136/thorax-2022-219792. Epub 2023 Apr 3. Thorax. 2023. PMID: 37012071 Clinical Trial.
iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer.
Furukawa Y, Ishii M, Ando J, Ikeda K, Igarashi KJ, Kinoshita S, Azusawa Y, Toyota T, Honda T, Nakanishi M, Ohshima K, Masuda A, Yoshida E, Kitade M, Porteus M, Terao Y, Nakauchi H, Ando M. Furukawa Y, et al. Among authors: ando m. Cell Rep Med. 2023 Dec 19;4(12):101327. doi: 10.1016/j.xcrm.2023.101327. Epub 2023 Dec 12. Cell Rep Med. 2023. PMID: 38091985 Free PMC article.
Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
Okamoto I, Nokihara H, Nomura S, Niho S, Sugawara S, Horinouchi H, Azuma K, Yoneshima Y, Murakami H, Hosomi Y, Atagi S, Ozaki T, Horiike A, Fujita Y, Okamoto H, Ando M, Yamamoto N, Ohe Y, Nakagawa K. Okamoto I, et al. Among authors: ando m. JAMA Oncol. 2020 May 1;6(5):e196828. doi: 10.1001/jamaoncol.2019.6828. Epub 2020 May 14. JAMA Oncol. 2020. PMID: 32163097 Free PMC article. Clinical Trial.
Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018).
Takashima A, Hamaguchi T, Mizusawa J, Nagashima F, Ando M, Ojima H, Denda T, Watanabe J, Shinozaki K, Baba H, Asayama M, Hasegawa S, Masuishi T, Nakata K, Tsukamoto S, Katayama H, Nakamura K, Fukuda H, Kanemitsu Y, Shimada Y; Colorectal Cancer Study Group in Japan Clinical Oncology Group (JCOG). Takashima A, et al. Among authors: ando m. J Clin Oncol. 2024 Nov 20;42(33):3967-3976. doi: 10.1200/JCO.23.02722. Epub 2024 Aug 26. J Clin Oncol. 2024. PMID: 39186709 Clinical Trial.
Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Di Lorenzo C, Khlevner J, Rodriguez-Araujo G, Xie W, Huh SY, Ando M, Hyams JS, Nurko S, Benninga MA, Simon M, Hewson ME, Saps M. Di Lorenzo C, et al. Among authors: ando m. Lancet Gastroenterol Hepatol. 2024 Mar;9(3):238-250. doi: 10.1016/S2468-1253(23)00398-9. Epub 2024 Jan 8. Lancet Gastroenterol Hepatol. 2024. PMID: 38211604 Clinical Trial.
Atazanavir nephrotoxicity.
Hara M, Suganuma A, Yanagisawa N, Imamura A, Hishima T, Ando M. Hara M, et al. Among authors: ando m. Clin Kidney J. 2015 Apr;8(2):137-42. doi: 10.1093/ckj/sfv015. Epub 2015 Mar 20. Clin Kidney J. 2015. PMID: 25815168 Free PMC article.
Primary Lymphoma of the Pericardium.
Kinoshita S, Ando J, Ando M, Komatsu N. Kinoshita S, et al. Among authors: ando m. Intern Med. 2021 Dec 15;60(24):4005-4006. doi: 10.2169/internalmedicine.7643-21. Epub 2021 Jun 12. Intern Med. 2021. PMID: 34121016 Free PMC article. No abstract available.
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Shide K, Takenaka K, Kitanaka A, Numata A, Kameda T, Yamauchi T, Inagaki A, Mizuno S, Takami A, Ito S, Hagihara M, Usuki K, Maekawa T, Sunami K, Ueda Y, Tsutsui M, Ando M, Komatsu N, Ozawa K, Kurokawa M, Arai S, Mitani K, Akashi K, Shimoda K. Shide K, et al. Among authors: ando m. Ann Hematol. 2024 Jan;103(1):97-103. doi: 10.1007/s00277-023-05528-4. Epub 2023 Nov 10. Ann Hematol. 2024. PMID: 37946031
3,437 results